At-home diagnostics startup Inito has raised $29 million in a Series B funding round led by Bertelsmann India Investments, with participation from existing investor Fireside Ventures. The fresh round follows the company’s $6 million Series A funding in November 2023 and brings total equity funding to $45 million. The new capital will support Inito’s expansion beyond fertility testing into broader hormone and health diagnostics, powered by AI-driven antibody engineering.
Funding to Drive Expansion and Innovation
As per report of ET, The Series B funding is set to accelerate the startup Inito’s growth and help scale its product offerings. Co-founders Aayush Rai and Varun AV stated that the funds will be primarily invested in research and development of synthetic antibodies, building a stable foundation for at-home diagnostic tests. This capital injection also reflects growing investor confidence in India’s healthtech and diagnostics sector, which is witnessing increased demand for accessible, AI-powered testing solutions.
Pioneering At-Home Fertility Testing in India
Inito launched in 2021 with an innovative at-home fertility device capable of measuring four hormone markers. The device interprets results using proprietary models, giving users personalized insights into their fertility health. Since its launch, the platform has processed over 30 million data points globally, underlining its reliability and scale. The success of the fertility device has enabled Inito to plan expansion into tests for additional biomarkers, addressing broader women’s and general health needs.
Read More: Bengaluru Startup SuperBryn Raises 1.2 Million to Make Voice AI Smarter and More Reliable
How Inito is Innovating with Synthetic Antibodies?
The next phase of Inito’s growth focuses on computational protein design to develop synthetic antibodies. Unlike traditional antibody development, which relies on animal-derived material and manual screening, this AI-enabled approach ensures stability, consistency, and scalability. Synthetic antibodies will allow Inito to create at-home diagnostic tests for health indicators that previously required clinical infrastructure, making health monitoring easier and more reliable for consumers.
Expanding Presence and Future Plans
Inito currently operates teams across Bengaluru, Dubai, and London and holds over 20 patents linked to its testing platform. The company is building tests for testosterone, thyroid, vitamins, and other analytes, aiming to cater to a wider health-monitoring audience. With the Series B funding, the startup Inito plans to accelerate product development, strengthen its presence in India, and set new benchmarks in the at-home diagnostics industry.
The funding round highlights the rising investor interest in India’s healthtech sector. By leveraging AI and synthetic antibodies, Inito is poised to redefine at-home health diagnostics, offering a convenient, reliable, and accessible solution to consumers across India and beyond.